Immunization, HepB3 in High income
High income: Immunization, HepB3 was 91.4% in 2024. ◆ Volatile
Immunization, HepB3 in High income, 1985–2024
Source: World Health Organization (WHO). Measured in % of one-year-old children.
Analysis
In 2024, immunization, hepb3 in High income stood at 91.4%.
That represents a change of up 16.9% over ten years.
Over the whole period, immunization, hepb3 in High income peaked at 91.7% in 2019 and was at its lowest, 0.0%, in 1985.
That places High income 7th out of 47 groups with data for 2024, putting it in the top quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Immunization, HepB3 in High income, year by year
| Year | % of one-year-old children | Change |
|---|---|---|
| 1985 | 0.0% | — |
| 1986 | 0.0% | — |
| 1987 | 0.0% | — |
| 1988 | 0.0% | — |
| 1989 | 0.0% | — |
| 1990 | 2.2% | — |
| 1991 | 7.3% | +229.1% |
| 1992 | 7.9% | +7.5% |
| 1993 | 13.8% | +74.9% |
| 1994 | 22.1% | +60.7% |
| 1995 | 35.3% | +59.9% |
| 1996 | 44.4% | +25.6% |
| 1997 | 47.6% | +7.4% |
| 1998 | 51.2% | +7.6% |
| 1999 | 52.3% | +2.2% |
| 2000 | 54.1% | +3.4% |
| 2001 | 60.5% | +11.8% |
| 2002 | 65.0% | +7.5% |
| 2003 | 68.0% | +4.5% |
| 2004 | 69.5% | +2.2% |
| 2005 | 70.5% | +1.5% |
| 2006 | 72.4% | +2.7% |
| 2007 | 72.6% | +0.2% |
| 2008 | 73.9% | +1.8% |
| 2009 | 74.1% | +0.2% |
| 2010 | 75.3% | +1.7% |
| 2011 | 76.6% | +1.8% |
| 2012 | 76.5% | -0.2% |
| 2013 | 77.1% | +0.8% |
| 2014 | 78.2% | +1.4% |
| 2015 | 78.9% | +0.9% |
| 2016 | 79.6% | +0.9% |
| 2017 | 79.5% | -0.1% |
| 2018 | 79.6% | +0.0% |
| 2019 | 91.7% | +15.3% |
| 2020 | 91.0% | -0.8% |
| 2021 | 91.7% | +0.7% |
| 2022 | 91.7% | +0.0% |
| 2023 | 91.4% | -0.3% |
| 2024 | 91.4% | +0.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1980s | 0.0% | 0.0% | 0.0% | 5 |
| 1990s | 28.4% | 2.2% | 52.3% | 10 |
| 2000s | 68.1% | 54.1% | 74.1% | 10 |
| 2010s | 79.3% | 75.3% | 91.7% | 10 |
| 2020s | 91.4% | 91.0% | 91.7% | 5 |
More health data for High income
- Population ages 60-64, male, annual growth rate 0.4095 % change on previous year (2025)
- Population ages 65-69, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 65-69, female, annual growth rate 1.62 % change on previous year (2025)
- Population ages 60-64, male, per capita 0.0308 units per person (2025)
- Population ages 60-64, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 60-64, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 55-59, male, per capita 0.032 units per person (2025)
- Population ages 60-64, female, annual growth rate 0.0537 % change on previous year (2025)
- Population ages 65-69, female, per capita 0.0305 units per person (2025)
- Population ages 60-64, female, per capita 0.0326 units per person (2025)
Frequently asked questions
- What is immunization, hepb3 in High income?
- Immunization, hepb3 in High income was 91.4% in 2024, according to World Health Organization (WHO).
- What is the highest immunization, hepb3 recorded in High income?
- The highest recorded value was 91.7% in 2019.
- What is the lowest immunization, hepb3 recorded in High income?
- The lowest recorded value was 0.0% in 1985.
- How does High income rank for immunization, hepb3?
- High income ranks 7th out of 47 groups with data for 2024.
- Is immunization, hepb3 rising or falling in High income?
- Over the last ten years it is up 16.9%. The long-run trend across the full record is volatile.
- Where does this High income data come from?
- The figures come from World Health Organization (WHO), published as part of Immunization, HepB3 (% of one-year-old children). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 40 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization rate, hepatitis B is the percentage of children ages 12-23 months who received hepatitis B vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized after three doses.